<DOC>
	<DOCNO>NCT00732056</DOCNO>
	<brief_summary>The purpose study determine maximum tolerate dose ( MTD ) GRN163L combination paclitaxel bevacizumab patient locally recurrent metastatic breast cancer ( MBC )</brief_summary>
	<brief_title>A Study GRN163L With Paclitaxel Bevacizumab Treat Patients With Locally Recurrent Or Metastatic Breast Cancer</brief_title>
	<detailed_description>GRN163L telomerase template antagonist vitro vivo activity variety tumor model system . Telomerase enzyme active primarily tumor cell crucial indefinite growth tumor cell . Inhibition telomerase may result antineoplastic effect .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>Histologically cytologically confirm adenocarcinoma breast measurable locally recurrent metastatic disease May one prior nontaxane chemotherapy regimen metastatic disease If HER2 positive , must prior treatment trastuzumab ( Herceptin® ) If previously treat anthracycline , anthracenedione , trastuzumab must test MUGA scan echocardiogram LVEF ≥ 50 % Must recover recent radiation treatment surgical procedure ECOG performance status 0 1 Life expectancy ≥ 3 month Locally recurrent disease amenable resection curative intent Prior adjuvant neoadjuvant taxane chemotherapy within 12 month prior first study drug administration Investigational therapy within 4 week prior first study drug administration Prior hormonal therapy within 2 week prior first study drug administration Prior radiotherapy within 2 week prior first study drug administration Cytotoxic chemotherapy within 2 week prior first study drug administration Therapeutic anticoagulation regular use antiplatelet therapy within 2 week prior first study drug administration NOTE : Lowdose anticoagulant therapy maintain patency vascular access device allow . Prolongation PT INR , aPTT &gt; ULN , fibrinogen &lt; LLN Active chronically current bleeding ( eg , active peptic ulcer ) Clinically significant cardiovascular cerebrovascular disease include Any history : Cerebrovascular disease include TIA , stroke subarachnoid hemorrhage Ischemic bowel Within last 12 month : MI Unstable angina NYHA grade II great CHF Grade 2 great peripheral vascular disease Active study entry : Uncontrolled hypertension define SBP &gt; 160 DBP &gt; 90 Uncontrolled clinically significant arrhythmia Clinically relevant active infection Nonhealing wound fracture Serious comorbid medical condition , include cirrhosis chronic obstructive chronic restrictive pulmonary disease Active autoimmune disease require immunosuppressive therapy Known positive serology HIV Prior malignancy ( within last 3 year ) except adequately treat basal cell squamous cell skin cancer , situ cervical cancer , situ breast cancer , situ prostate cancer , cancer patient diseasefree least 3 year Any severe , acute , chronic medical psychiatric condition , laboratory abnormality , difficult comply protocol requirement may increase risk associate study participation study drug administration may interfere interpretation study result , judgment investigator , would make patient inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Metastatic Breast Cancer</keyword>
	<keyword>Recurrent Breast Cancer</keyword>
</DOC>